Spread the love

Targeted Therapy in Breast Cancer Treatment

Targeted therapy is a specialized approach to treating breast cancer that focuses on specific molecular targets within cancer cells. Unlike traditional chemotherapy, which affects both healthy and cancerous cells, targeted therapy aims to selectively attack cancer cells while minimizing damage to normal cells.

Understanding Targeted Therapy

Targeted therapy involves the use of drugs that are designed to interfere with specific molecules involved in the growth and spread of cancer cells. These drugs work by blocking the signals that cancer cells need to grow and divide, or by targeting specific proteins or genes that are overexpressed in cancer cells.

In breast cancer treatment, targeted therapy is often used in combination with other treatments such as surgery, radiation therapy, and chemotherapy. It can be used at different stages of breast cancer, including as neoadjuvant therapy (before surgery) to shrink tumors, as adjuvant therapy (after surgery) to reduce the risk of cancer recurrence, or as palliative therapy to control the growth and spread of advanced breast cancer.

See also How does age affect cholesterol levels and cardiovascular health?

Types of Targeted Therapy for Breast Cancer

There are several types of targeted therapy drugs used in breast cancer treatment:

HER2-targeted therapy: Approximately 20% of breast cancers overexpress a protein called human epidermal growth factor receptor 2 (HER2). HER2-targeted therapies, such as trastuzumab (Herceptin) and pertuzumab (Perjeta), specifically target HER2-positive breast cancer cells, inhibiting their growth and reducing the risk of recurrence.

Hormone receptor-targeted therapy: Hormone receptor-positive breast cancers have receptors for estrogen or progesterone, which promote their growth. Hormone receptor-targeted therapies, such as tamoxifen and aromatase inhibitors, block the effects of these hormones, preventing cancer cell growth.

CDK4/6 inhibitors: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, such as palbociclib, ribociclib, and abemaciclib, are used in combination with hormone receptor-targeted therapy to further inhibit the growth of hormone receptor-positive breast cancer cells.

PARP inhibitors: Poly (ADP-ribose) polymerase (PARP) inhibitors, such as olaparib and talazoparib, are used in the treatment of certain types of breast cancer with BRCA1 or BRCA2 gene mutations. These drugs block the PARP enzyme, which helps repair damaged DNA, leading to the death of cancer cells.

See also What is the importance of assessing color vision during an eye exam?

Benefits and Limitations of Targeted Therapy

Targeted therapy offers several advantages over traditional chemotherapy in breast cancer treatment. It can be more effective in specifically targeting cancer cells, leading to improved treatment outcomes and reduced side effects. Additionally, targeted therapy can be tailored to the individual characteristics of a patient’s cancer, allowing for personalized treatment approaches.

However, targeted therapy is not without limitations. Resistance to targeted therapy can develop over time, leading to treatment failure. Additionally, targeted therapy drugs can be expensive and may not be accessible to all patients. Ongoing research is focused on identifying new targets and developing more effective targeted therapies to overcome these challenges.

See also How does a FODMAP diet help individuals with irritable bowel syndrome?

In conclusion, targeted therapy is a valuable approach in breast cancer treatment that focuses on specific molecular targets within cancer cells. By selectively attacking cancer cells, targeted therapy offers the potential for improved treatment outcomes and reduced side effects, providing hope for patients with breast cancer.

Keywords: targeted, breast, treatment, growth, receptor, hormone, inhibitors, specific, targets